FDAnews
www.fdanews.com/articles/84848-glenmark-s-dpp-iv-completes-phase-i-study

GLENMARK'S DPP-IV COMPLETES PHASE I STUDY

February 24, 2006

Glenmark Pharmaceuticals has announced that its lead DPP-IV inhibitor candidate for diabetes, GRC 8200, has successfully completed a Phase I study.

GRC 8200 has now entered Phase II testing, with trials that are beginning in South Africa. The company also intends to file an investigational new drug application for GRC 8200 by May 2006 for further Phase II clinical testing and expects to complete all Phase II trials by March 2007.